Descriptive study of psychotropic use in the 20-35 age adults with autism in Languedoc-Roussillon;Étude descriptive de l'utilisation de psychotropes chez les personnes autistes de 20 à 35 ans en institution du Languedoc-Roussillon

Encephale

Volumn 31, Issue 3, 2005, Pages 302-308

  Baghdadli, A ^a   Gonnier, V ^a   Valancogne, F ^b   Aussilloux, C ^c  

^a Centre de Ressources Autisme Languedoc Roussillon   (France)

^b Centre Hospitalier de Montpellier   (France)

^c SMPEA Peyre Plantade   (France)

Author keywords

Adaptative profile; Adults; Autism; Descriptive study; Pervasive developmental disorders; Psycho active treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADULT; AGGRESSIVENESS; AGITATION; ANXIETY; ARTICLE; AUTISM; DAILY LIFE ACTIVITY; EPILEPSY; FEMALE; HUMAN; INSTITUTIONAL CARE; INTERPERSONAL COMMUNICATION; MALE; PRESCRIPTION; PSYCHIATRIC DIAGNOSIS; SOCIAL ADAPTATION; SOCIALIZATION; ADAPTIVE BEHAVIOR; COMMUNICATION DISORDER; CROSS-SECTIONAL STUDY; FRANCE; INSTITUTIONALIZATION; MENTAL HEALTH SERVICE; QUESTIONNAIRE; RESIDENTIAL CARE; STATISTICS; UTILIZATION REVIEW;

ADAPTATION, PSYCHOLOGICAL; ADULT; AUTISTIC DISORDER; CATCHMENT AREA (HEALTH); COMMUNICATION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HUMANS; INSTITUTIONALIZATION; MALE; MENTAL HEALTH SERVICES; PRESCRIPTIONS, DRUG; PSYCHOTROPIC DRUGS; QUESTIONNAIRES; SOCIALIZATION;

EID: 22544485113     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0013-7006(05)82394-2     Document Type: Article

References (34)

1. AMAN MG, COLLIER-CRESPIN A, LINDSAY RL. Pharmacotherapy of disorders in mental retardation. Eur Child Adolesc Psychiatry 2000; 9: 98-107.
2. AMAN MG, VAN BOURGONDIER ME, WOLFORD PL et al. Psychotropic and anticonvulsant drug in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry 1995; 34: 1672-81.
3. AUSSILLOUX C, BAGHDADLI A, BURSZTEJN C. et al. Recherche sur les facteurs d'évolution de l'autisme: caractéristiques initiales d'une cohorte de 193 enfants autistes de moins de 7 ans. Neuropsychiatr Enf Adolesc 2001; 49: 96-107.
4. AZEMA B, BARTHEYE E. Difficultés d'orientation et d'accueil des enfants autistes et psychotiques. Plan régional CREAI Languedoc-Roussillon, 1996.
5. BAGHDADLI A, GONNIER V, AUSSILLOUX C. Revue des traitements psychopharmacologiques de l'autisme chez l'adolescent et l'adulte. Encephale 2002; XXVIII: 248-54.
6. BUITELAR et al. Medication treatment in subjects with autistic spectrum disorders. Eur Child Adolesc Psychiatry 2000; 9: 85-97.
7. CAMPBELL M, CUEVA J. Pharmacology in child and adolescent psychiatry: a review of the past seven years. Part 1. J Am Child Adolesc Psychiatry 1995; 34: 1124-32.
8. CARTER AS, VOLKMAR FR et al. The Vineland Adaptative Behavior Scale, supplementary norms for individuals with autism. J Aut Develop Disord 1998; 28, 4: 287-302
9. COOK EH Jr, ROWLETT R, JASELSKIS C et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31: 739-45.
10. FOMBONNE E. The epidemiology of autism, a review. Psychol Med 1999; 29: 769-86.
11. GILLBERG C, COLEMAN M. Autism and medical disorders. A review of the literature. Develop Med Child Neurol 1996; 38: 191-202.
12. GILLBERG C. The treatment of epilepsy in autism. J Aut Develop Disord 1991; 21: 61-77.
13. GRINGAS P. Practical paediatric psychopharmacological prescribing in autism: the potential and the pitfalls. Autism 2000; 4 (3): 229-47.
14. HOWLIN P, GOODE S, HUTTON J et al. Adult outcome for children with autism. J Child Psychol Psychiatry 2004; 45: 212-29.
15. KING BH. Pharmacological treatment of mood disturbances, aggression and self-injury in persons with pervasive developmental disorders. JADD 2000; 30 (5): 439-45.
16. MAC DOUGLE ChJ, NAYLOR S, COHEN DJ et al. A double blind placebo controlled study of fluvoxamine in adults with autistic disorders. Arch Gen Psychiatry 1996; 53: 1001-8.
17. MAC DOUGLE ChJ et al. A double-blind placebo-controlled study of Risperidone in adults with autistic disorders and other pervasive developmental disorders. Arch Gen Psychiatry 1998; 55: 633-41.
18. MANZANO J, LAMUNIERE MC, PECKOVA M. L'enfant psychotique devenu adulte. Résultat d'une étude catamnestique de vingt années sur 100 cas. Neuropsychiatr Enf 1987; 35 (10): 429-43.
19. ORGANISATION MONDIALE DE LA SANTE. CIM 10, ICD 10. Classification internationale des troubles mentaux et des troubles du comportement. Critères diagnostiques pour la recherche. Paris-Milan-Londres: Masson, 1994.
20. PERRY A, FACTOR DC. Psychometric validity and clinical use fulness of the Vineland Adaptative Behavior Scale. J Aut Develop Disord 1989; 19: 41-55.
21. POSEY DJ, McDOUGLE CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 2000; 8 (2): 45-63.
22. ROBERTSON J, EMERSON E, GREGORY N et al. Receipt of psychotropic medication by people with intellectual disability in residential settings. J Intellect Disability Research 2000; 44: 666-76.
23. RUTTERM. Autistic Children: infancy to adulthood. Sem Psychiatry 1970; 2: 435-50.
24. SAFER DJ. Changing patterns of psychotropic medications prescribe by child psychiatrists in the 1990. J Child Adolesc Psychopharmacol 1997; 7 (4): 267-74.
25. SPARROW S, BALLA D, CICCHETTI D. Vineland adaptative behaviour scale. Circle Pines, MN: American Guidance Service, 1984.
26. STEIN D et al. Brief report: Children with autism as they grow-up - Description of adult inpatients with severe autism. J Aut Develop Disord 2001; 31 (3): 355-60.
27. THE UKU SIDE EFFECT RATING SCALE. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psy Scand 1987; 76: 334.
28. TSAI LY. Psychopharmacology in autism. Psychosom Med 1999; 61: 651-65.
29. VOLAVKA J. Neurobiology of violence. Washington DC: American Psychiatric Press, 1995.
30. VOLKMAR F et al. Practice parameters for the assessment and treatment of children, adolescents and adults with autism and other pervasive developmental disorders. J Am Acad Child Adolesc. Psychiatry 1998; 38: 32S-54S.
31. VOLKMAR FR, NELSON DS. Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry 1995; 29: 127-9.
32. VON FRENCKELL R. Assessment Manual for Psychopharmacology. National Institute of Mental Health (ed), Early Clinical Drug Evaluation Unit, 1976.
33. WILLEMSEN-SWINKELS SH, BUITELAAR JK, NIJHOF GJ et al. Failure of naltrexone hydrochloride to reduce self injurious and autistic behaviour in mentally retarded adults : double blind placebo controlled studies. Arch Gen Psychiatry 1995; 52: 766-73.
34. WILLIAMS H et al. Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability. J Int Dis Res 2000; 44: 164-9.